Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT00094159 Completed - Neoplasms Clinical Trials

Safety Assessment of Weekly Intravenous Infusions of SNS-595 for the Treatment of Solid Tumors

Start date: October 2004
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine whether SNS-595 given intravenously weekly for 3 weeks is safe.

NCT ID: NCT00094003 Completed - Neoplasm Metastasis Clinical Trials

Study of NS-9 in Patients With Liver Metastases

Start date: September 2002
Phase: Phase 1
Study type: Interventional

This study is to investigate the safety of NS-9 and to see how well it is tolerated in patients with cancer that has metastasized (spread) to the liver from another primary tumor. NS-9 is a drug developed to go to the liver to cause cell death specifically in tumor cells. This study is also set up to determine the best dose to use.

NCT ID: NCT00093821 Completed - Clinical trials for Recurrent Childhood Acute Lymphoblastic Leukemia

Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors

Start date: September 2004
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of tanespimycin in treating young patients with recurrent or refractory leukemia or selected solid tumors. Drugs used in chemotherapy, such as tanespimycin, work in different ways to stop cancer cells from dividing so they stop growing or die.

NCT ID: NCT00091806 Completed - Solid Tumors Clinical Trials

Two Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors

Start date: August 2004
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and pharmacokinetics of two dose schedules of panitumumab in subjects with advanced solid tumors.

NCT ID: NCT00091585 Completed - Neoplasms Clinical Trials

Initial Safety Assessment of SNS-595 for the Treatment of Solid Tumors.

Start date: June 2004
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine whether SNS-595 given intravenously once every 3 weeks is safe.

NCT ID: NCT00091182 Completed - Clinical trials for Recurrent Rectal Cancer

Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment

Start date: October 2004
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well oxaliplatin works in treating young patients with recurrent solid tumors that have not responded to previous treatment. Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.

NCT ID: NCT00091117 Completed - Malignant Neoplasm Clinical Trials

Bortezomib in Treating Patients With Advanced Cancer and Liver Dysfunction

Start date: July 2004
Phase: Phase 1
Study type: Interventional

Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for their growth. This phase I trial is studying the side effects and best dose of bortezomib in treating patients with advanced cancer and liver dysfunction.

NCT ID: NCT00090389 Completed - Endometriosis Clinical Trials

Acupuncture for Women's Health Conditions

Start date: January 2005
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of acupuncture in treating women's health conditions.

NCT ID: NCT00089011 Completed - Clinical trials for Recurrent Mantle Cell Lymphoma

Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer

Start date: April 2004
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well tacrolimus and mycophenolate mofetil works in preventing graft-versus-host disease in patients who have undergone total-body irradiation (TBI) with or without fludarabine phosphate followed by donor peripheral blood stem cell transplant for hematologic cancer. Giving low doses of chemotherapy, such as fludarabine phosphate, and TBI before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune system and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving tacrolimus and mycophenolate mofetil after the transplant may stop this from happening.

NCT ID: NCT00088790 Completed - Neoplasms Clinical Trials

AZD5438 in Patients With Advanced Solid Malignancies

Start date: July 2004
Phase: Phase 1
Study type: Interventional

Purpose of this study is to assess the safety and tolerability of AZD5438 given orally to patients with advanced solid malignancies A review of the emerging clinical tolerability and exposure data from this study in conjunction with preclinical and the available clinical pharmacodynamic data relating to AZD5438, led to a decision by AstraZeneca that the development of AZD5438 as a potential anti-cancer agent would be discontinued.